Peera Hemarajata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/566116/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Investigation of a Suspect Severe Acute Respiratory Syndrome Coronavirus-2 and Influenza A Mixed Outbreak: Lessons Learned for Long-Term Care Facilities Nationwide. Clinical Infectious Diseases, 2021, 73, S77-S80.	2.9	1
2	When Should Asymptomatic Persons Be Tested for COVID-19?. Journal of Clinical Microbiology, 2020, 59, .	1.8	17
3	The Frequency of Discordant Gyrase A Genotypes Among Cases of Multiple Neisseria gonorrhoeae Infections at Different Anatomic Sites. Sexually Transmitted Diseases, 2019, 46, e3-e4.	0.8	1
4	Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. Journal of Antimicrobial Chemotherapy, 2019, 74, 1241-1243.	1.3	72
5	A multisite implementation of a real-time polymerase chain reaction assay to predict ciprofloxacin susceptibility in Neisseria gonorrhoeae. Diagnostic Microbiology and Infectious Disease, 2019, 94, 213-217.	0.8	9
6	Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2019, 68, 2045-2052.	2.9	43
7	Selection of hyperproduction of AmpC and SME-1 in a carbapenem-resistant Serratia marcescens isolate during antibiotic therapy. Journal of Antimicrobial Chemotherapy, 2018, 73, 1256-1262.	1.3	13
8	Ciprofloxacin May be Efficacious in Treating Wild-Type Gyrase A Genotype Neisseria gonorrhoeae Infections. Sexually Transmitted Diseases, 2018, 45, e18-e18.	0.8	10
9	A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection. Sexually Transmitted Diseases, 2018, 45, 87-91.	0.8	11
10	Unusual carbapenem resistant but ceftriaxone and cefepime susceptible Klebsiella oxytoca isolated from a blood culture: Case report and whole-genome sequencing investigation. IDCases, 2018, 11, 9-11.	0.4	8
11	Variability of Daptomycin MIC Values for Enterococcus faecium When Measured by Reference Broth Microdilution and Gradient Diffusion Tests. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	28
12	Implementation of a Rapid Genotypic Assay to Promote Targeted Ciprofloxacin Therapy of <i>Neisseria gonorrhoeae</i> in a Large Health System. Clinical Infectious Diseases, 2017, 64, ciw864.	2.9	51
13	Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	85
14	Reply to "Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory—a Response from the Front Line― Journal of Clinical Microbiology, 2017, 55, 983-984.	1.8	1
15	Pediatric vaccine-strain herpes zoster: a case series. Pediatric Dermatology, 2017, 34, 665-667.	0.5	9
16	O05.6â€The impact of a rapid genotypicneisseria gonorrhoeaeassay on targeted ciprofloxacin therapy. , 2017, , .		0
17	Duodenoscope-Related Outbreak of a Carbapenem-Resistant Klebsiella pneumoniae Identified Using Advanced Molecular Diagnostics. Clinical Infectious Diseases, 2017, 65, 1159-1166.	2.9	61
18	Evolution and Transmission of Carbapenem-Resistant Klebsiella pneumoniae Expressing the blaOXA-232 Gene During an Institutional Outbreak Associated With Endoscopic Retrograde Cholangiopancreatography. Clinical Infectious Diseases, 2017, 64, 894-901.	2.9	39

PEERA HEMARAJATA

#	Article	IF	CITATIONS
19	Real-Time PCR Targeting the <i>penA</i> Mosaic XXXIV Type for Prediction of Extended-Spectrum-Cephalosporin Susceptibility in Clinical Neisseria gonorrhoeae Isolates. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	13
20	Epidemiology of Neisseria gonorrhoeae Gyrase A Genotype, Los Angeles, California, USA. Emerging Infectious Diseases, 2017, 23, 1581-1584.	2.0	5
21	P1.31â€The costs of targeted ciprofloxacin therapy vs. empiric therapy forneisseria gonorrhoeaeinfections over a thirteen-month study period. , 2017, , .		1
22	Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity. Antimicrobial Agents and Chemotherapy, 2017, 61,	1.4	121
23	Microbial recovery from clot-activating Vacutainers $\hat{A}^{\textcircled{o}}$. Diagnostic Microbiology and Infectious Disease, 2016, 85, 395-397.	0.8	0
24	FolC2â€mediated folate metabolism contributes to suppression of inflammation by probiotic <i>Lactobacillus reuteri</i> . MicrobiologyOpen, 2016, 5, 802-818.	1.2	44
25	Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory. Journal of Clinical Microbiology, 2016, 54, 2866-2873.	1.8	39
26	Generation and validation of a universal perinatal database and biospecimen repository: PeriBank. Journal of Perinatology, 2016, 36, 921-929.	0.9	36
27	Staphylococcus saprophyticus Bacteremia in a Pediatric Patient with Central Venous Catheter-Associated Infection. Clinical Microbiology Newsletter, 2016, 38, 153-157.	0.4	0
28	Investigation of a suspected nosocomial transmission of blaKPC3-mediated carbapenem-resistant Klebsiella pneumoniae by whole genome sequencing. Diagnostic Microbiology and Infectious Disease, 2016, 84, 337-342.	0.8	11
29	Risk factors associated with the transmission ofÂcarbapenem-resistant Enterobacteriaceae viaÂcontaminatedÂduodenoscopes. Gastrointestinal Endoscopy, 2016, 83, 1121-1129.	0.5	68
30	Performance and Verification of a Real-Time PCR Assay Targeting the <i>gyrA</i> Gene for Prediction of Ciprofloxacin Resistance in Neisseria gonorrhoeae. Journal of Clinical Microbiology, 2016, 54, 805-808.	1.8	43
31	First Report of Ventriculoperitoneal Shunt Infection due toCyberlindnera fabianii. Case Reports in Infectious Diseases, 2015, 2015, 1-6.	0.2	10
32	First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate. Antimicrobial Agents and Chemotherapy, 2015, 59, 6605-6607.	1.4	207
33	Development of a Novel Real-Time PCR Assay with High-Resolution Melt Analysis To Detect and Differentiate OXA-48-Like β-Lactamases in Carbapenem-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2015, 59, 5574-5580.	1.4	31
34	Identification of a proton-chloride antiporter (EriC) by Himar1 transposon mutagenesis in Lactobacillus reuteri and its role in histamine production. Antonie Van Leeuwenhoek, 2014, 105, 579-592.	0.7	9
35	The Human Gut Microbiome and Body Metabolism: Implications for Obesity and Diabetes. Clinical Chemistry, 2013, 59, 617-628.	1.5	271
36	Lactobacillus reuteri-Specific Immunoregulatory Gene <i>rsiR</i> Modulates Histamine Production and Immunomodulation by Lactobacillus reuteri. Journal of Bacteriology, 2013, 195, 5567-5576.	1.0	53

#	Article	IF	CITATIONS
37	Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therapeutic Advances in Gastroenterology, 2013, 6, 39-51.	1.4	716
38	Histamine Derived from Probiotic Lactobacillus reuteri Suppresses TNF via Modulation of PKA and ERK Signaling. PLoS ONE, 2012, 7, e31951.	1.1	363
39	Microbial Genomics and Pathogen Discovery. , 0, , 238-251.		1